MODELING THE TRANSITION TO THE FOURTH EPIDEMIOLOGIC STAGE OF INFLAMMATORY BOWEL DISEASE: PREVALENCE EQUILIBRIUM

Joseph Windsor,Lindsay Hracs,Michael Cummings,Julia Gorospe,Michael Buie,Joshua Quan,Ante Markovinovic,Lea Caplan,Quinn Goddard,Tyler Williamson,Yvonne Abbey,Maria Abreu,Raja Ali,Murdani Abdullah,Mansour Altuwaijri,Vineet Ahuja,Domingo Balderramo,Rupa Banerjee,Eric Benchimol,Charles Bernstein,Eduard Brunet-Mas,Johan Burisch,Iris Dotan,Usha Dutta,Sara El Ouali,Angela Forbes,Richard Gearry,Viet Hang Dao,Juanda Hartono,Ida Hilmi,Fabian Julian-Banos,Jamilya Kaibullayeva,Paul Kelly,Paulo Kotze,Peter Lakatos,Charlie Lees,Julajak Limsrivilai,Edward Loftus,Jonas Ludvigsson,Joyce Mak,Ka Kei Ng,Ola Olen,Remo Panaccione,Mukesh Paudel,Abel Quaresma,David Rubin,Marcellus Simadibrata,Yang Sun,Hidekazu Suzuki,Martin Toro,Dan Turner,Beatriz Iade Vergara,Shu-Chen Wei,Jesus Yamamoto-Furusho,Kuk-Kyun Yang,Siew Ng,Stephanie Coward,Gilaad Kaplan

DOI: https://doi.org/10.1093/ibd/izae020.073

2024-01-25

Inflammatory Bowel Diseases

Abstract:Abstract BACKGROUND A theoretical framework for population-level transition across four epidemiologic stages has been proposed for inflammatory bowel disease (IBD): 1. Emergence (low incidence/prevalence); 2. Acceleration in Incidence (rapid rising incidence); 3. Compounding Prevalence (stabilizing incidence, rapid rising prevalence); and 4. Prevalence Equilibrium (decelerated prevalence), which no region has entered yet. Many regions of the early-industrialized world (North America, Europe, Oceania) are currently in stage 3. AIM To model the transition to the 4th epidemiologic stage of IBD based on real-world data. METHODS Transition to stage 4 involves deceleration of prevalence after a period of rapid increase. Age-specific, population-based incidence and prevalence data from Canada (2007–2014, >97% of population) were used to model changing prevalence using a partial differential equation (PDE) derived from a compartment model (Figure 1). The PDE is built on an average historical incidence value (2007–2014) and accounts for changing population age distributions over time. The PDE prevalence output was internally validated by comparing observed historical prevalence values with model outputs. After validation, the model was used to forecast future age-stratified prevalence and provide an estimate for when the transition to stage 4 is expected. Although incidence is predicted to stabilize in stage 3, the PDE was run on five scenarios to account for variability in future incidence values; therefore, we modeled annual incidence increases of 2% and 1%, stable incidence, and annual incidence decreases of 1% and 2%. RESULTS Internal validation of the model compared observed to predicted prevalence values in 2014: The observed prevalence was 0.677%; the model output was 0.678%. The model predicts gradual prevalence deceleration across 2020–2043 (Figure 2). In 2043, prevalence is modeled to range between 1.101% and 1.293% across incidence scenarios (−2% to 2%). Assuming a stable incidence, as predicted by stage 3, the increase in prevalence slows from a difference in annual percent change of 0.021% in 2020 to 0.011% in 2043, signalling transition towards stage 4 (Figure 2). DISCUSSION Stage 3 (Compounding Prevalence) is characterized by a stabilizing incidence trend, and rapid growth in prevalence. Without a growing incidence rate, the IBD population continues to age until mortality approximates incidence, thereby allowing prevalence to stabilize (Stage 4). Understanding the markers of epidemiologic transition and predicting the future population distribution (age, prevalence) of IBD allows healthcare administrators to anticipate the future needs of gastroenterology clinics to continue offering timely, high-quality care and prepare for an aging IBD population with complications from long-standing disease, age-related comorbidities, and polypharmacy. Figure 1 Compartment model that feeds the partial differential equation. The compartment model has three states: healthy (H), diseased (S), and dead (D); the i = incidence; r = remission, and m0 = mortality rates are dependent on age (a) and time (i), where as m1 = mortality rate is dependent on age, time, and possibly duration of disease (d). Figure 2 Modeled time-dependent prevalence of IBD in Canada for 2%, 1%, 0%, −1%, and −2% change in annual incidence (2015–2043).

gastroenterology & hepatology